Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18235987 | 0.85 | POLB (0.38) | CYP19A1POLBKMT2ASRC | |
| SCHEMBL3730288 | 0.83 | NOTUM (0.49) | CYP4F2CYP4A11POLBKMT2AHTT | |
| SCHEMBL28759020 | 0.83 | CYP4F2 (0.43) | CYP4F2CYP4A11POLBKMT2AHTT | |
| SCHEMBL21063617 | 0.81 | MAOA (0.47) | CYP4F2CYP4A11POLBKMT2AHTT | |
| SCHEMBL4675850 | 0.81 | CYP4F2 (0.43) | CYP4F2CYP4A11POLBKMT2AHTT | |
| SCHEMBL2628207 | 0.81 | CYP4F2 (0.40) | CYP4F2CYP4A11POLBKMT2AHTT | |
| SCHEMBL18605543 | 0.81 | CYP4F2 (0.40) | CYP4F2CYP4A11POLBKMT2AHTT | |
| SCHEMBL15199191 | 0.81 | MAOB (0.43) | CYP4F2CYP4A11POLBKMT2AHTT | |
| SCHEMBL21063549 | 0.81 | CYP4F2 (0.40) | CYP4F2CYP4A11POLBKMT2A | |
| SCHEMBL16967984 | 0.81 | DGAT1 (0.50) | CYP4F2CYP4A11CYP19A1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4276059-A2 | CHEMICALLY ENCODED SPATIALLY ADDRESSED LIBRARY SCREENING PLATFORMS | City of Hope (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2022-04-28 | — | — | US | disclosed |
| WO-2021079984-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | 大日本住友製薬株式会社 | 2021-04-29 | — | — | WO | disclosed |
| EP-3777898-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20190275181-A1 | Compounds for Positron Emission Tomography | ENDOCYTE INC (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3533473-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018053517-A1 | INHIBITORS OF LDLR-PCSK9 PROTEIN-PROTEIN INTERACTION AND METHODS OF THEIR USE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | ENDOCYTE, INC | 2016-10-06 | — | — | US | disclosed |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | ENDOCYTE, INC | 2016-10-06 | — | — | US | disclosed |
| US-20150320891-A1 | Radioiodinated Fatty Acids | GE HEALTHCARE LIMITED (GG) | 2015-11-12 | — | — | US | disclosed |
| US-9138493-B2 | Radioiodinated fatty acids | GE HEALTHCARE LIMITED (GB) | 2015-09-22 | — | — | US | disclosed |
| WO-2015073678-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | ENDOCYTE, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20130272960-A1 | RADIOIODINATED FATTY ACIDS | GE HEALTHCARE LIMITED (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20120100073-A1 | PET RADIOTRACERS FOR IMAGING FATTY ACID METABOLISM AND STORAGE | WASHINGTON UNIVERSITY (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320891-A1 | Radioiodinated Fatty Acids | FFAR3, FFAR1, FFAR2 | CYP4F2 330/4885CYP4A11 887/4885CYP19A1 533/4885 |
| US-20130272960-A1 | RADIOIODINATED FATTY ACIDS | FFAR3, FFAR1, FFAR2 | CYP4F2 330/4885CYP4A11 887/4885CYP19A1 533/4885 |
| US-20190275181-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | CYP4F2 2553/4885CYP4A11 4702/4885CYP19A1 2977/4885 |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | CYP4F2 2553/4885CYP4A11 4702/4885CYP19A1 2977/4885 |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | FOLH1, FOLR2, FOLR1 | CYP4F2 2553/4885CYP4A11 4702/4885CYP19A1 2977/4885 |
| US-20120100073-A1 | PET RADIOTRACERS FOR IMAGING FATTY ACID METABOLISM AND STORAGE | LIPC, PNLIP, FFAR1 | CYP4F2 341/4885CYP4A11 1438/4885CYP19A1 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.